Can Trump lower prescription drug prices? Here's why U.S. drug costs are so high.
What to know about President Trump's executive order plans aimed at slashing drug prices
President Trump signed an executive order Monday that will attempt to bring down the cost of some drugs in the United States — but why are drug prices so high to begin with?
On average, Americans pay almost three times as much for prescription drugs as people in other high-income countries like the U.K., Germany or France, according to a 2024 report published by the nonprofit research organization RAND. For some medications, the cost difference is even steeper. A month of insulin, for example, costs about $100 in the U.S., compared to only about $10 in France, RAND found.
In large part, this comes down to price negotiations.
"You're talking about contrasting us with countries that have essentially universal health care, where you have the government that is paying for everything, negotiating for all the drug prices," Dr. Céline Gounder, CBS News medical contributor and editor-at-large for public health at KFF Health News, said Monday. "So when you have one player that's negotiating on behalf of the entire population, you just have a lot more negotiating power."
The closest comparison in the U.S. is likely Medicare, the federal health insurance program for people over 65 years old, Gounder said, but that doesn't cover all Americans. Additionally, the ability for Medicare to negotiate drug prices didn't happen until the Inflation Reduction Act was signed into law in 2022 by President Joe Biden and it only allows for negotiations of "a small fraction of all prescription drugs," Gounder said.
Because the U.S. doesn't have universal health care, "we don't have one negotiator for our drug prices," Gounder said.
Most Americans have private health insurance, and the prices they pay for prescriptions are negotiated through Pharmacy Benefit Managers or PBMs.
In theory, PBMs should help control growth in drug prices due to their ability to negotiate manufacturer rebates and other cost-effectiveness options, according to the Commonwealth Fund, a nonprofit foundation that advocates for health equity.
"But PBMs have financial incentives that may contribute to growth in drug prices, higher patient out-of-pocket costs, and the closing of independent pharmacies in rural areas and low-income neighborhoods," the group notes on its website.
Last year, the Federal Trade Commission called out pharmacy benefit managers — often described as prescription drug middlemen — for benefiting off of inflated drug prices. PBMs wield enormous control over the availability and cost of drugs, the FTC said in a report released in July 2024.
In a more recent January report, the FTC said three major PBMs hiked costs for a wide range of lifesaving drugs, including medications to treat heart disease and cancer. Some prices were marked up by hundreds and sometimes thousands of percent, the FTC found.
Will Trump's executive order help lower drug prices?
It's uncertain if Mr. Trump's executive order can make headway on drug prices, and what drugs would even be affected.
Gounder pointed to a similar effort during his first presidency, which only applied to drugs given by providers in hospitals and clinics through Medicare Part B, that failed.
"The last time he proposed this in 2020, this was contested in the federal courts and did not hold up," Gounder said.
To really change how drug prices are negotiated in the U.S., Congress would need to act, she said.
Plus, "Pharmaceutical companies are among the biggest lobbying presences in Washington, D.C. They are, of course, opposed to this," Gounder said.
The pharmaceutical industry has argued that lower prices will affect innovation and development of new medicines.
"Applying other countries' antiquated approach to how they value — and pay — for medicines will stall investment across America's biotech companies, risk access to vital treatments and cures for millions of American patients, and lead to fewer American jobs," John F. Crowley, president of the advocacy group Biotechnology Innovation Organization, said in a statement Monday.
To change how much influence pharmaceutical companies have would also require an act of Congress in the form of campaign finance reform, Gounder said.
Patients For Affordable Drugs Now, a national patient advocacy organization, said in a statement that several aspects of the Mr. Trump's order raise questions.
"This Executive Order is a step in the right direction, but without additional guardrails, it leaves room for pharmaceutical companies to continue gaming the system at the expense of patients," the statement read. "The reality is: drug companies set high prices in the U.S. because U.S. policy lets them — unlike other high income countries that negotiate lower prices."
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
19 minutes ago
- Yahoo
Tulsi Gabbard Flips Sides in MAGA Civil War Over Iran's Nuclear Capabilities
Director of National Intelligence Tulsi Gabbard has flipped her stance on Iran after President Donald Trump nuked her intelligence as 'wrong.' Gabbard told the Senate Intelligence Committee on March 25 that there was no intelligence to suggest Iran was building nuclear weapons, though the country had enriched its uranium to higher levels. Following Israeli Prime Minister Benjamin Netanyahu's June 12 'preemptive' strike on Iran—which he justified by saying that the country has a 'secret plan' to weaponize uranium—Trump sided with Israel's countervailing position. On two separate occasions this week, Trump rebuffed Gabbard's earlier assessment of Iran's nuclear program. 'I don't care what [Gabbard] said,' Trump said aboard Air Force One. 'I think they were very close to having one.' In another comment on Wednesday, the president added that Iran was 'a few weeks' away from turning their uranium into a weapon, echoing similar sentiments shared by Netanyahu. Then on Friday, Gabbard fell in line with Trump, attacking the media for having the gall to believe what she said. 'The dishonest media is intentionally taking my testimony out of context and spreading fake news as a way to manufacture division,' Gabbard wrote to her 600K followers. 'America has intelligence that Iran is at the point that it can produce a nuclear weapon within weeks to months, if they decide to finalize the assembly.' She added, 'President Trump has been clear that can't happen, and I agree.' Gabbard included a clip of what she called her 'full testimony,' which has since racked up 8.9 million views. The world has been thrown into a state of limbo while Trump weighs a decision on whether to get the United States involved in strikes on Iran, a decision the country warned would be 'very dangerous.' In a statement read on Thursday by White House Press Secretary Karoline Leavitt, Trump said he would make his decision 'within the next two weeks' based on the fact that there 'is a substantial chance of negotiations that may or may not take place with Iran in the near future.' Reuters reported that the Iranian Foreign Minister Abbas Araghchi met with a group of European diplomats in Geneva on Friday for nuclear talks.
Newsweek
28 minutes ago
- Newsweek
US B-2 Stealth Bombers on the Move Across Pacific
Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources. Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content. As the fighting between Israel and Iran continues, six B-2 stealth bombers departed Whiteman Air Force Base in Missouri and are en route to Guam, according to U.S. officials confirmed to Fox News and flight tracking data analyzed by multiple news outlets. Newsweek reached out the Pentagon's Defense Press Operations office and the White House via email on Saturday for comment. NITRO KC135s returning to Altus AFB, OK B2s MYTEE11 FLT & MYTEE21 FLT continuing westbound to destination Andersen AFB, Guam. — Aircraft Spots (@AircraftSpots) June 21, 2025 Why It Matters This month, the conflict between Israel and Iran has escalated dramatically, with President Donald Trump calling for the evacuation of Tehran, Iran's capital city home to over 9.5 million people. Israel initially struck Tehran and several other cities in "Operation Rising Lion," a campaign it said was meant to preempt a planned Iranian attack and disrupt Iran's nuclear capabilities. Iran, which has said its nuclear program is for peaceful purposes, has since retaliated, though Israeli defense systems—bolstered by U.S. military technology—have intercepted about 99 percent of incoming missile fire, according to Israeli officials on Saturday morning in an X, formerly Twitter, post. Iran hit a hospital in southern Israel on Thursday, and local reports noted that buildings in Tel Aviv were on fire from Iranian missiles on Friday. Israel's strikes have killed at least 585 people in Iran—including 239 civilians—and wounded another 1,300, according to a human rights group that has long tracked the country, Washington-based Human Rights Activists. Iran's government has not offered overall casualty figures. Israel has said 24 people have been killed since Friday and 500 more have been wounded, according to Israeli officials. The U.S. is Israel's closest ally, providing billions of dollars in military aid annually. Following the 1979 Iranian Revolution, diplomatic relations between the U.S. and Iran disintegrated, and the two countries have held strained, distrusting relations over the past four-decades. Iran's nuclear program has long been a focal point of U.S. and Israeli concern, with Iran insisting its efforts are solely for energy purposes. The second Trump administration had been involved in talks with Iran ahead of the conflict, although no formal diplomacy has come out of it. During his first presidency, Trump withdrew from the Joint Comprehensive Plan of Action (JCPOA), known as the Iran Nuclear Deal. B-2s and Bunker-Buster Bombs The B-2 can carry two 15-ton bunker-buster bombs—which only the U.S. possesses, making these aircraft critical to any potential operation against Iran's most fortified nuclear sites. Officials and experts have suggested that the U.S.'s 30,000-pound (13,000kg) bunker-buster bomb is the only weapon capable of destroying the Fordow Fuel Enrichment Plant, a facility believed to be central to Tehran's nuclear program and carved deep into a mountain. The movement signals the U.S. may be positioning military assets to provide Trump with operational options as the Israel-Iran conflict intensifies. A B-2 Stealth Bomber opens the 135th Rose Parade Presented by Honda on January 1, 2024, in Pasadena, California. A B-2 Stealth Bomber opens the 135th Rose Parade Presented by Honda on January 1, 2024, in Pasadena, To Know The bombers apparently refueled after launching from Missouri, suggesting they launched without full fuel tanks due to a heavy onboard payload, which could potentially be bunker-buster bombs. The deployment comes as Trump prepares to meet with his national security team to discuss potential U.S. involvement in Israeli strikes against Iranian nuclear facilities. According to The New York Times, air traffic control communications showed the B-2 aircraft taking off from Whiteman Air Force Base in Missouri. Iran's most advanced and hardened nuclear facility, the Fordow plant in the country's northwest, is a fortress. Built inside a mountain some 300 feet underground and reinforced by layers of concrete, the plant, which is the most likely target of a potential American strike, is impenetrable by any bomb except the GBU-57 Massive Ordnance Penetrator (MOP). The B-2 Spirit, a U.S. stealth bomber, is currently the only aircraft designed to deploy the GBU-57 and can carry two bunker buster bombs at a time. Military experts note that destroying such fortified targets would likely require multiple precision strikes at the exact same location. Earlier on Saturday, Israel launched a wave of airstrikes against missile sites and a nuclear facility in Iran, while Iran fired a barrage of ballistic missiles and launched drones into Israel. What People Are Saying Director of National Intelligence (DNI) Tulsi Gabbard wrote on X on Friday: "America has intelligence that Iran is at the point that it can produce a nuclear weapon within weeks to months, if they decide to finalize the assembly. President Trump has been clear that can't happen, and I agree." President Donald Trump earlier this week wrote on Truth Social: "We know exactly where the so-called 'Supreme Leader' is hiding. He is an easy target, but is safe there - We are not going to take him out (kill!), at least not for now. But we don't want missiles shot at civilians, or American soldiers. Our patience is wearing thin. Thank you for your attention to this matter!" Iran's Supreme Leader Ayatollah Ali Khamenei, in a national address, in part: "We warn America of the consequences of engaging in war, because it will suffer severe damage if it decides to do so. War is met with war, bombing with bombing, and strike with strike." Iran's foreign minister Abbas Araghchi on X on Wednesday: "Iran solely acts in self-defense. Even in the face of the most outrageous aggression against our people, Iran has so far only retaliated against the Israeli regime and not those who are aiding and abetting it. Just like Netanyahu manufactured this war to destroy diplomacy, the world should be highly alarmed about increasing attempts by the failing Israeli regime to get others to bail it out and to expand the flames to the region and beyond." What Happens Next Trump will make a decision on whether to have the U.S. join Israel's war with Iran "within the next two weeks," according to White House press secretary Karoline Leavitt, who told reporters Thursday that the decision is based on Trump's view of whether Iran "may" or "may not" agree to a diplomatic resolution through negotiations over its nuclear program. The president is expected to receive intelligence briefings with the National Security Council (NSC) over the weekend as he considers possible actions against Iran.
Hamilton Spectator
36 minutes ago
- Hamilton Spectator
Rejecting Trump's rhetoric, Maine's governor heads to Maritimes to build ties
HALIFAX - Maine's governor is heading to the Maritimes next week with hopes a charm offensive will slow the rapid drop in Canadian tourist visits to her state. In a release issued Friday, Janet Mills says she's aware the historically close relationship between New England and its northern neighbours has been challenged by U.S. president Donald Trump's tariffs and his rhetoric about Canada becoming the 51st state. According to U.S. federal border crossing data released Friday, 85,000 fewer Canadians entered Maine in May than in the same month a year ago, a drop of about 27 per cent. The governor says she will spend three days meeting with premiers, appearing in local media and visiting businesses in hope of sending a message that Maritimers remain 'welcome in Maine' despite Trump's trade policies. On Monday, the governor will stop in Saint John, N.B., where she intends to visit businesses with links to Maine and she then will travel to Fredericton to hold talks with New Brunswick Premier Susan Holt. On Wednesday, Mills will meet with Nova Scotia Premier Tim Houston in Halifax and tour a marine technology centre. Last month, the governor unveiled new, bilingual signs welcoming Canadian visitors, which are being placed in windows around the state. On June 13, in her weekly radio address, Mills said she wants to ensure the 'historic friendship and deeply intertwined economies last for generations to come.' 'It's not just our economies – we are connected so deeply by mutual economic advantages and on centuries-old familial, cuisine, language, and cultural bonds that far supersede politics,' she told her listeners, reminding them that Canada is the United States' closest and most important trading partner. The Democratic Party member said Trump's 'roller coaster tariffs' are unsettling business in her state and 'making our Canadian neighbors feel unwelcome in the United States.' In 2024, nearly 800,000 Canadian visitors spent approximately US$498 million in Maine, according to the state's Office of Tourism. Overall, the data showed Maine welcomed 14.8 million visitors, who spent more than US$9.2 billion, supporting 115,900 jobs and generating US$5.4 billion in wages. This report by The Canadian Press was first published June 21, 2025. Error! Sorry, there was an error processing your request. There was a problem with the recaptcha. Please try again. You may unsubscribe at any time. By signing up, you agree to our terms of use and privacy policy . This site is protected by reCAPTCHA and the Google privacy policy and terms of service apply. Want more of the latest from us? Sign up for more at our newsletter page .
